Industry led consortium accelerates regenerative medicine sector
An industry-led consortium is set to begin projects that will link industry partners with regenerative medicine academic research and boost the growth of this emerging sector. The consortium, called the Regenerative Medicine Industry Interface, will accelerate commercialisation and…
New Hudson Institute Director and CEO announced
We are pleased to announce that Professor Elizabeth Hartland has accepted a position as the new Director and CEO of Hudson Institute of Medical Research. Professor Hartland obtained her BSc (Hons) majoring in Microbiology and Biochemistry and subsequently…
BioCurate CEO Appointed
An outstanding industry leader with exceptional national and global experience in successfully propelling important biomedical discoveries out of the lab and into the market has been appointed inaugural CEO of BioCurate Pty Ltd. This AUD $80 million venture…
Westpac Businesses of Tomorrow 2017 – Trajan Scientific and Medical Top 20
Right from our very beginning in 1817, Westpac has been guided by the same purpose: TO SUPPORT THE ECONOMIC PROGRESS OF AUSTRALIAN BUSINESSES. As we reach our 200th anniversary, that guiding purpose remains. To help the next generation…
Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy
Allergy immunotherapy company ProTA Therapeutics Pty Ltd (ProTA) will accelerate the development of a possible treatment for life-threatening peanut allergy with the appointment of its new CEO. ProTA has appointed former Mesoblast Vice President Operations Dr. Suzanne Lipe,…
Bionic Vision Technologies raises $US18m from State Path Capital, China Huarong
The Australian university-owned company in the race to develop a bionic eye to restore sight has been saved from its own near plunge into darkness after raising $US18 million ($23.6 million) from Chinese investors including the nephew of Hong…
The Medical Technologies and Pharmaceuticals (MTP) Roadmap – unlocking future growth opportunities for Australia
A changing global landscape The global MTP industry is on the cusp of enormous growth globally due to a range of factors including ageing populations, the growth of emerging markets seeking better health services and unprecedented innovation in…
New abilities to enhance cancer research at the Australian Synchrotron
It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer. The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new…
Easing the pain of global expansion
Two years after going global, Australian healthcare company Medical Developments International (MDI) which manufactures the acute pain killer Penthrox (commonly known as ‘the green whistle’) has opened a new facility in Melbourne Assisted by CSIRO, MDI has seen…
Opthea Launches A$45 Million Financing to Progress OPT- 302 Expanded Clinical Development
Opthea Limited (ASX:OPT) (“Opthea”), a developer of novel biologic therapies for the treatment of eye diseases, today announced the launch of an entitlement offer and institutional placement (collectively the “Offer”) to raise approximately A$45 million. Proceeds from the…
Bone, cartilage and tissue; we’ve cracked the trifecta (and it’s made of titanium and plastic)
We’ve been quietly working away in Melbourne on something big. The big trifecta of a bone, cartilage and tissue implant. The first of its kind. More specifically, a 3D printed titanium and polymer sternum to suit individual patients. …
The US drug pricing debate: Managing risks to results
EY report on drug pricing The unsustainable trajectory of the health care spending in the US is generating much dialog and consternation across a variety of stakeholders including governments, industry, media academic think-tanks and the general public. Prescription…
